focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPz Cussons Regulatory News (PZC)

Share Price Information for Pz Cussons (PZC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 114.60
Bid: 114.20
Ask: 115.00
Change: 0.60 (0.53%)
Spread: 0.80 (0.701%)
Open: 111.80
High: 116.00
Low: 111.40
Prev. Close: 114.00
PZC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

22 Sep 2021 07:00

RNS Number : 5280M
PZ CUSSONS PLC
22 September 2021
 

22 September 2021

 

Returning to growth and continued strategic progress

 

PZ Cussons plc ("PZ Cussons" or the "Group") today issues the following trading update in respect of its first quarter of the new financial year to 31 May 2022, ended 28 August 2021.

 

 

Performance Highlights

 

§ As expected, unprecedented demand for our Hygiene brands at the beginning of the Covid-19 pandemic impacted year-on-year revenue comparisons in the first quarter of FY22.

 

§ Two-year Q1 revenue (1) grew +13%, with growth across each of our core categories of Hygiene, Baby and Beauty and in all geographic regions. Must Win Brands were up +23%.

 

§ One-year Q1 revenue (1) declined -9%, driven by Hygiene. The Baby and Beauty categories showed strong price / mix improvement, with Hygiene held back by unusually low levels of promotional discounting on Carex in the prior year.

 

§ Total business performance improved as the quarter progressed and we returned to growth in August. Assuming no further disruption, we expect to return to growth for Q2.

 

§ Must Win Brands declined -20% versus the prior year. Excluding Carex, revenue grew +4%.

 

- The decline was entirely driven by our Hygiene category, with Carex in the UK experiencing double-digit decline. The UK washing & bathing category has shown encouraging momentum as we emerge from Covid-19 restrictions. Carex is the clear market leader in hand hygiene, with revenue up over 40% versus two years ago.

- Sales of Baby products were flat. Covid-19 restrictions in Indonesia weighed more heavily than expected but are starting to moderate.

- Beauty grew double-digit, including our hair brands recovering from social restrictions.

 

§ Net debt reduced further in the first quarter of the new financial year, down to £23m, due in part to the proceeds from the five:am disposal, further narrowing our Food & Nutrition portfolio.

 

§ Despite the significant inflationary pressure on our cost base, assuming no further cost headwinds or global supply or other Covid-related disruption, we expect to deliver FY22 adjusted profit before tax within the current range of expectations.

 

 

Delivering our new strategy: Building brands for life. Today and for future generations

 

§ Q1 marketing investment increased over 20%, with the majority of the spend on Must Win Brands.

 

§ As input cost pressures increase, we have successfully executed price increases across our brand portfolios in Nigeria and Indonesia. In our developed markets, in addition to more targeted price increases, our Revenue Growth Management focus has been to drive brand equity improvements and efficient levels of price promotion to enable further price / mix improvements.

 

§ Simplification of our Nigerian business, including halving our supplier base and consolidating our distribution centres.

 

§ Continued progress developing capabilities and evolving our culture. Building on improved employee engagement scores we have launched a new company purpose, appointed new senior leaders and started a transformation programme to upgrade our people processes and systems.

 

 

Jonathan Myers, Chief Executive Officer, commented:

 

"The medium-term outlook remains in line with our expectations and we have confidence that our brand and market portfolio will emerge strongly once we cycle through the unprecedented demand for hygiene products at the start of the pandemic.

 

We continue to navigate the well-publicised inflationary pressures on commodities and freight. We have a co-ordinated effort underway to reduce product, manufacturing and logistics costs that the consumer does not value while also accelerating our Revenue Growth Management plans to drive price / mix. Combined with sustained and more effective marketing investment, stronger brand plans and new product innovation, these interventions mean that, assuming no further disruptions, we expect to return to growth for Q2 and to deliver low to mid single-digit revenue growth for the year, in line with our strategic financial framework we outlined at the Capital Markets Day in March. Despite the significant inflationary pressure on our cost base, assuming no further cost headwinds or global supply or other Covid-related disruption, we expect to deliver FY22 adjusted profit before tax within the current range of expectations."

 

Quarter 1

Revenue (£m)

Two-year growth (1)

One-year growth (1)

Europe & Americas

42.4

+7%

(28%)

Asia Pacific

40.4

+3%

(5%)

Africa

47.5

+31%

+15%

Central

1.1

(24%)

(51%)

Group

131.4

+13%

(9%)

 

(1) Revenue growth is quoted on a like-for-like organic basis, after the impact of acquired and disposed of brands or businesses, and at constant currency. Two-year growth rates included due to the short-term distorting effect of Covid-19.

 

Notes to editors

Figures are unaudited, and not subject to review by the Group's auditors

 

Cautionary note regarding forward-looking statements

This announcement contains certain forward-looking statements relating to expected or anticipated results, performance or events. Such statements are subject to normal risks associated with the uncertainties in our business, supply chain and consumer demand along with risks associated with macro-economic, political and social factors in the markets in which we operate. Whilst we believe that the expectations reflected herein are reasonable based on the information we have as at the date of this announcement, actual outcomes may vary significantly owing to factors outside the control of the Group, such as cost of materials or demand for our products, or within our control such as our investment decisions, allocation of resources or changes to our plans or strategy. The Group expressly disclaims any obligation to revise forward-looking statements made in this or other announcements to reflect changes in our expectations or circumstances. No reliance may be placed on the forward-looking statements contained within this announcement.

 

For further enquiries, please contact

Investors Sarah Pollard, PZ Cussons plc - Chief Financial Officer 0161 435 1000

Media Tim Linacre / Guy Scarborough / Bryn Woodward - Instinctif 020 7457 2020

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUAAURAKUKUUR
Date   Source Headline
19th Sep 20061:30 pmRNSDirector/PDMR Shareholding
4th Sep 20064:14 pmRNSGrant of Options
1st Aug 20067:00 amRNSFinal Results
1st Jun 20069:00 amRNSDirectorate Change
1st Jun 20067:01 amRNSPre-Close Update
6th Apr 20064:34 pmRNSDirectors interest in Shares
5th Apr 20061:09 pmRNSDirectors Interest in Shares
22nd Mar 200612:25 pmRNSDirectors Interest in Shares
3rd Mar 200611:30 amRNSDirectors Interest in Shares
1st Mar 20067:01 amRNSDirectorate Change
9th Feb 20068:48 amRNSDirector/PDMR Shareholding
7th Feb 20067:01 amRNSInterim Results
24th Jan 20067:00 amRNSNotice of Results
3rd Jan 20067:30 amRNSDirector Declaration
4th Oct 20059:00 amRNSDirectorate Change
3rd Oct 200510:20 amRNSDirectorate Change
26th Sep 200512:00 pmRNSAGM Statement
19th Sep 20053:21 pmRNSDirectors Interest in Shares
9th Sep 200510:36 amRNSDirectors Interest in Shares
8th Sep 200512:40 pmRNSDirectors Interest in Shares
24th Aug 20052:34 pmRNSDirectors Interest in Shares
15th Aug 20054:10 pmRNSDirectors Interest in Shares
2nd Aug 20057:01 amRNSFinal Results
28th Jul 20053:31 pmRNSNotice of Results
22nd Jul 200511:00 amRNSDirectorate Change
28th Jun 200512:35 pmRNSResult of Meetings
7th Jun 200512:00 pmRNSDirectorate Change
3rd Jun 20051:20 pmRNSNotice of EGM
2nd Jun 20057:01 amRNSProposed enfranchisement
1st Jun 20059:00 amRNSDirector Declaration
5th May 200512:00 pmRNSDirectorate Change
9th Mar 20054:43 pmRNSSecond Price Monitoring Extn
9th Mar 20054:38 pmRNSPrice Monitoring Extension
8th Feb 20057:00 amRNSInterim Results
10th Jan 20051:09 pmRNSNotice of Results
4th Jan 200510:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.